
    
      30 elderly patients age 60-85 with primary CNS DLBCL who will achieve response CR or PR will
      enter the study protocol maintenance phase.

      Induction treatment will include Rituximab and high dose methotrexate protocol (containing at
      least methotrexate and one more chemotherapy agent).

      Patients with MRI documented response CR or PR will enter the study protocol maintenance
      phase.

      Maintenance: 28 day cycles of Ibrutinib 560 mg orally once daily until relapse or disease
      progression or occurrence of limiting toxicities

      Evaluation of response:

      Radiologic evaluation by MRI will be performed every 3 months. Neurologic status evaluation
      every 2 months Neurocognitive evaluation every 6 months
    
  